679 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This large-scale Phase 3 trial is crucial for understanding the long-term cardiovascular impact of survodutide, a novel anti-obesity agent. A positive outcome would establish survodutide as a safe and effective treatm…
These hypothetical findings suggest that GLP-1 receptor agonists like Liraglutide or GIK infusions could offer safer and more effective perioperative glycemic control for patients with Type II Diabetes Mellitus underg…
Understanding the real-world effectiveness of combination therapies like Xultophy® is crucial for optimizing Type 2 Diabetes management. This study provides valuable data on how a fixed-ratio combination of insulin de…
This study provides compelling evidence that combining cagrilintide and semaglutide offers a highly effective and synergistic therapeutic strategy for achieving substantial and clinically meaningful weight loss, surpa…
The Cagrilintide-Semaglutide combination group demonstrated a remarkable mean body weight reduction of 22.6% from baseline over the 68-week study period, which was statistically significantly superior to all other gro…
This study provides compelling evidence that CagriSema not only facilitates significant weight loss but also directly and substantially improves blood pressure in individuals with overweight or obesity and hypertensio…
This study provides valuable real-world evidence regarding the effectiveness and utilization of liraglutide for weight management outside of controlled clinical trial settings. The findings can help inform healthcare …
Developing long-acting GLP-1 receptor agonists is paramount for improving patient adherence and convenience in the long-term management of Type 2 Diabetes. If LAPS-Exendin (HM11260C) demonstrates favorable safety and …
This study is significant because it investigates strategies to improve the long-term management of Type 2 Diabetes, moving beyond conventional insulin regimens. The expected findings suggest that combining insulin wi…
Understanding the pharmacokinetic equivalence and performance of different CagriSema formulations and delivery devices is crucial for its continued development as a combination therapy for obesity. This study's findin…
This meta-analysis provides compelling evidence that CagriSema, combining a GLP-1 receptor agonist (semaglutide) with an amylin analog (cagrilintide), offers a substantially more potent and effective treatment option …
While specific pharmacokinetic data (e.g., Cmax, AUC values) are not detailed in this record, the study successfully completed its Phase 1 objectives, enrolling 40 participants and evaluating the drug exposures over a…
This review underscores the critical and enduring role of bariatric surgery as the most efficacious treatment for obesity, even amidst the revolutionary advancements in GLP-1 RA pharmacotherapy. Recognizing the unique…
Cagrisema represents a highly potent and promising new therapeutic option for individuals struggling with obesity, offering superior weight loss efficacy and improved metabolic parameters compared to current gold-stan…
This comprehensive review underscores Semaglutide's position as a highly effective pharmacological intervention for obesity, offering substantial and sustained weight loss that can significantly improve health outcome…
Mazdutide's dual GLP-1R and GCGR agonism offers a unique mechanism that appears to drive superior weight loss and broader metabolic improvements compared to single-target therapies. This comprehensive metabolic benefi…
This research solidifies Liraglutide's role as a cornerstone therapy for managing Type 2 Diabetes and Obesity, offering not only robust glycemic control and significant weight reduction but also crucial cardiovascular…
This study is crucial because it focuses on affordable and accessible interventions for a population disproportionately affected by metabolic and cardiovascular diseases. Identifying effective, well-tolerated, and cos…
This Phase 1 study is a crucial step in the development of a potentially improved oral semaglutide formulation. Understanding the pharmacokinetics of oral semaglutide D under various dosing conditions is essential for…
This study is crucial for understanding the mechanisms by which semaglutide promotes weight loss and improves metabolic health, particularly at the 2.4 mg dose. The anticipated significant slowing of gastric emptying …
This large-scale data analysis is crucial for understanding the potential neuroprotective effects of different diabetes medications. If Semaglutide demonstrates a significantly lower risk of dementia/Alzheimer's disea…
If successful, this study could identify a simple, accessible, and enjoyable dietary intervention to optimize the benefits of GLP-1 therapy, potentially mitigating unwanted muscle loss and enhancing overall health out…
This review provides a novel mechanistic framework that integrates gut health with musculoskeletal well-being, suggesting that GLP-1 could be a pivotal therapeutic target. Understanding this "gut-GLP-1-musculoskeletal…
This study provides compelling evidence, through a robust model-informed approach, that oral semaglutide 25 mg could offer a highly effective and convenient treatment option for obesity and type 2 diabetes. The conven…
This case report highlights a rare but significant potential adverse effect of semaglutide, suggesting it may induce hypercapnia in susceptible individuals even with normal lung function. This finding underscores the …
This comprehensive critique offers crucial insights for clinicians and patients, suggesting that the current evidence does not strongly support a direct causal link between GLP-1 RAs and NAION, which may help alleviat…
Preserving lean body mass during weight loss is crucial for maintaining metabolic health, physical strength, and preventing conditions like sarcopenia (age-related muscle loss). If successful, this study could provide…
If successful, this trial could identify a novel dietary supplement, AMPK Charge+®, that effectively improves glycemic control in individuals with prediabetes or Type 2 Diabetes. The potential for AMPK Charge+® to enh…
Successfully managing the gastrointestinal side effects of incretin-based anti-obesity medications is crucial for improving patient compliance and achieving optimal weight loss outcomes. This study's findings could es…
This study is crucial for understanding how lifestyle interventions like endurance exercise can complement pharmacological treatments such as semaglutide in managing Type 2 Diabetes. The key implication is that a comb…
Preserving lean muscle mass is critical for maintaining metabolic health, strength, and overall quality of life during significant weight loss. If successful, this intervention could become a standard recommendation f…
This systematic review provides strong, synthesized evidence supporting the neuroprotective potential of GLP-1 receptor agonists in Alzheimer's disease, moving beyond individual study observations. The consistent find…
These findings are profoundly significant, as they demonstrate semaglutide's potential to not only improve metabolic health and liver steatosis but also to reverse biological aging at an epigenetic level. This suggest…
This study highlights a critical safety consideration for patients undergoing free flap breast reconstruction who are also using GLP-1 RAs. The observed increase in serious wound complications, particularly flap necro…
This study provides a robust, integrated safety profile for widely used GLP-1 RAs, offering a more complete picture than individual studies alone. Understanding these comprehensive safety data is crucial for informing…
This study provides crucial economic evidence for healthcare payers and policymakers in the US, suggesting that the superior efficacy of tirzepatide translates into significant long-term health benefits and a favorabl…
This study provides crucial initial evidence that KN069's novel dual mechanism—acting as a GLP-1R (glucagon-like peptide-1 receptor) agonist (mimicking a hormone that promotes insulin release and reduces appetite) and…
This research provides crucial real-world evidence suggesting that semaglutide may not only manage obesity and type 2 diabetes but also potentially offer protective or beneficial effects on skeletal health, particular…
This research highlights the profound benefits of GLP-1 receptor agonist therapy in adolescents with obesity, demonstrating not just weight reduction but a critical improvement in body composition by preferentially re…
This comprehensive meta-analysis provides compelling real-world evidence that GLP-1-based therapies offer substantial benefits beyond glycemic control and cardiovascular protection, extending to critical limb outcomes…
This study provides compelling real-world evidence that tirzepatide offers superior benefits in preventing the progression of cardiovascular-kidney-metabolic syndrome compared to other GLP-1 receptor agonists. The sig…
This study provides critical insights into the pharmacovigilance of drug-associated ketoacidosis, highlighting specific drug classes that warrant increased clinical vigilance. The strong signal for SGLT2 inhibitors re…
Developing new, potentially improved formulations of existing, effective drugs is crucial for enhancing patient convenience, adherence, and broader accessibility. If oral semaglutide D proves to be equally safe and ef…
The completion of this large Phase 3 trial is a significant milestone, as it represents a robust effort to explore a novel therapeutic avenue for Alzheimer's disease. If the results demonstrate a positive effect, it c…